Lineage Cell Therapeutics (LCTX) Non Operating Investment Income (2018 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Non Operating Investment Income of $24000.0 for Q1 2026, up 580.0% year-over-year from $3529.4 in Q1 2025, and up 442.86% quarter-over-quarter from -$7000.0 in Q4 2025.
Powered by 
Analysis
Lineage Cell Therapeutics (LCTX) Non Operating Investment Income (2018 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Non Operating Investment Income history runs 9 years deep, the most recent figure standing at $24000.0 for Q1 2026.
- In Q1 2026, Non Operating Investment Income rose 580.0% year-over-year to $24000.0; the TTM figure through Mar 2026 stood at $21000.0 (up 362.5% YoY), while the FY2025 annual figure was -$8000.0, changed 0.0% from the prior year.
- Non Operating Investment Income for Q1 2026 stood at $24000.0, up from -$7000.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $40000.0 in Q1 2023, with the low at -$517000.0 in Q4 2022.
- The 5-year median for Non Operating Investment Income is -$6000.0 (2023), against an average of -$61200.0.
- The sharpest annual moves came in 2025 and 2026: Non Operating Investment Income slumped 153.85% in 2025, then surged 580.0% in 2026.
- Lineage Cell Therapeutics' Non Operating Investment Income stood at -$517000.0 in 2022, then surged by 98.84% to -$6000.0 in 2023, then soared by 316.67% to $13000.0 in 2024, then slumped by 153.85% to -$7000.0 in 2025, then jumped by 442.86% to $24000.0 in 2026.
- Business Quant data shows LCTX's Non Operating Investment Income at $24000.0 in Q1 2026, -$7000.0 in Q4 2025, and $6000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Lineage Cell Therapeutics | 270.71 Mn | 213.99 Mn | 1.07 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 24,000.00 |
| Dec 31, 2025 | -7,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Jun 30, 2025 | -2,000.00 |
| Mar 31, 2025 | -5,000.00 |
| Dec 31, 2024 | 13,000.00 |
| Sep 30, 2024 | -6,000.00 |
| Jun 30, 2024 | -10,000.00 |
| Mar 31, 2024 | -5,000.00 |
| Dec 31, 2023 | -6,000.00 |
| Sep 30, 2023 | -60,000.00 |
| Jun 30, 2023 | -150,000.00 |
| Mar 31, 2023 | 40,000.00 |
| Dec 31, 2022 | -517,000.00 |
| Sep 30, 2022 | -233,000.00 |
| Jun 30, 2022 | -709,000.00 |
| Mar 31, 2022 | -735,000.00 |
| Sep 30, 2021 | -2.45 Mn |
| Jun 30, 2021 | 590,000.00 |
| Mar 31, 2021 | 6.02 Mn |